2024 Meta-Analysis Indicates That GLP-1RAs Reduce Adverse CV Events GLP1-RA therapy significantly reduces the risk of major adverse cardiovascular events (MACEs), all-cause mortality, CV mortality, stroke, risk for coronary revascularization, and composite adverse kidney outcomes in both sexes, regardless of a patient's history of cardiovascular disease, BMI or eGFR (Rivera et al, 2024)
Endocrinology (2013) 154:48
BPC-157 promotes angiogenesis and accelerates healing of muscles, tendons, ligaments, and the gut lining
However, a clear unmet need remains in supporting patients beyond pharmacological treatment, particularly in addressing nutrition gaps and preserving muscle health during therapy," said Dr Reddy's Laboratories CEO, Global Generics and Dr Reddy's and Nestle Health Science Ltd Director, MV Ramana
This double delay leads to food sitting in the stomach longer, creating more gas and fermentation, and eventually causing discomfort and often stomach pressure
.png)
